Seagen Inc.
Combination Therapy With LIV1-ADC and PD-1 Antagonist

Abstract:

The present disclosure relates, in general, to methods for treating LIV-1-expressing cancers comprising administering an anti-LIV-1 antibody drug conjugate (LIV-1-ADC) in combination with a PD-1 antagonist, such as an anti-PD-1 antibody.